Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT06205706 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT06205706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06205706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Lead sponsor
BioInvent International AB
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 4, 2023
Completion date
November 7, 2028
Enrollment
35 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, non small cell lung cancer, solid tumors